Scientists Identify Target for Tackling Checkpoint-Inhibitor Resistance

Scientists have uncovered a mechanism by which tumors can become resistant to treatment with checkpoint inhibitors including anti-programmed death-ligand 1 (PD-L1) and anti-programmed cell death protein 1 (PD-1) antibodies, and suggest one way of reversing that resistance, by blocking the cytokine transforming growth factor-β (TGF-β).The discovery is based on findings from the 300-patient IMvigor210 biomarker study, the results from which led to FDA approval of the anti-PD-L1 antibody